| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $110.7M | -33.1% |
| SG&A Expense | $27.6M | -10.1% |
| Operating Income | -$138.3M | +29.5% |
| Pre-tax Income | -$128.5M | +34.2% |
| Income Tax | $0 | -100.0% |
| Net Income | -$128.5M | +38.0% |
| EPS (Basic) | -$7.58 | +39.0% |
| EPS (Diluted) | -$7.58 | +39.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $115.5M | -57.4% |
| Current Assets | $152.9M | -44.9% |
| Total Assets | $169.4M | -43.9% |
| Current Liabilities | $26.2M | -9.7% |
| Total Liabilities | $28.9M | -23.8% |
| Stockholders' Equity | $140.5M | -46.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$128.5M | +33.8% |
| Capital Expenditures | $92K | -97.3% |
| Investing Cash Flow | -$25.3M | -633.8% |
| Financing Cash Flow | $196K | -100.0% |
| Free Cash Flow | -$128.6M | +34.9% |